Datopotamab deruxtecan led to better progression-free survival and safety compared with standard chemotherapy in patients with metastatic HER-2 negative breast cancer.
AstraZeneca-Daiichi get some clarity on Enhertu follow up fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Partial responses observed in 5 of 19 evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib in heavily pretreated populationPartial response observed in 1 of. | May 25, 2023
eFFECTOR Therapeutics (EFTR) Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.